{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:59:58Z","timestamp":1790924398858,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7609","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2016,6,30]]},"DOI":"10.1038\/nature18600","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T15:46:14Z","timestamp":1466696774000},"page":"647-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":373,"title":["A combinatorial strategy for treating KRAS-mutant lung cancer"],"prefix":"10.1038","volume":"534","author":[{"given":"Eusebio","family":"Manchado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Weissmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Wullenkord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Lujambio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"BFnature18600_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11\u201322 (2003)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature18600_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013)","journal-title":"Nature"},{"key":"BFnature18600_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009)","journal-title":"Nature"},{"key":"BFnature18600_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2009.03.017","volume":"137","author":"C Scholl","year":"2009","unstructured":"Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821\u2013834 (2009)","journal-title":"Cell"},{"key":"BFnature18600_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"137","author":"J Luo","year":"2009","unstructured":"Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835\u2013848 (2009)","journal-title":"Cell"},{"key":"BFnature18600_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","volume":"25","author":"AG Stephen","year":"2014","unstructured":"Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging ras back in the ring. Cancer Cell 25, 272\u2013281 (2014)","journal-title":"Cancer Cell"},{"key":"BFnature18600_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nature Rev. Drug Discov. 13, 828\u2013851 (2014)","journal-title":"Nature Rev. Drug Discov"},{"key":"BFnature18600_CR8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3392","volume":"19","author":"P Lito","year":"2013","unstructured":"Lito, P., Rosen, N. & Solit, D. B. Tumor adaptation and resistance to RAF inhibitors. Nature Med. 19, 1401\u20131409 (2013)","journal-title":"Nature Med."},{"key":"BFnature18600_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar, A. A. & Poulikakos, P. I. Targeting RAS-ERK signalling in cancer: promises and challenges. Nature Rev. Drug Discov. 13, 928\u2013942 (2014)","journal-title":"Nature Rev. Drug Discov"},{"key":"BFnature18600_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710 (2014)","journal-title":"Cancer Cell"},{"key":"BFnature18600_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","volume":"7","author":"C Sun","year":"2014","unstructured":"Sun, C. et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Reports 7, 86\u201393 (2014)","journal-title":"Cell Reports"},{"key":"BFnature18600_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nbt.1720","volume":"29","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nature Biotechnol. 29, 79\u201383 (2011)","journal-title":"Nature Biotechnol."},{"key":"BFnature18600_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912\u20131934 (2002)","journal-title":"Science"},{"key":"BFnature18600_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","volume":"3","author":"EJ Morris","year":"2013","unstructured":"Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742\u2013750 (2013)","journal-title":"Cancer Discov"},{"key":"BFnature18600_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207\u2013221 (2014)","journal-title":"Cancer Cell"},{"key":"BFnature18600_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010)","journal-title":"Nature"},{"key":"BFnature18600_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 18, 683\u2013695 (2010)","journal-title":"Cancer Cell"},{"key":"BFnature18600_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012)","journal-title":"Cancer Discov"},{"key":"BFnature18600_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012)","journal-title":"Nature"},{"key":"BFnature18600_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012)","journal-title":"Cell"},{"key":"BFnature18600_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","volume":"89","author":"H Kouhara","year":"1997","unstructured":"Kouhara, H. et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway. Cell 89, 693\u2013702 (1997)","journal-title":"Cell"},{"key":"BFnature18600_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit, J. M. et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11, 690\u2013699 (2012)","journal-title":"Mol. Cancer Ther."},{"key":"BFnature18600_CR23","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/jm2006222","volume":"54","author":"V Guagnano","year":"2011","unstructured":"Guagnano, V. et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066\u20137083 (2011)","journal-title":"J. Med. Chem."},{"key":"BFnature18600_CR24","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine, P. R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045\u20132056 (2012)","journal-title":"Cancer Res."},{"key":"BFnature18600_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","volume":"5","author":"F Li","year":"2015","unstructured":"Li, F. et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 5, 438\u2013451 (2015)","journal-title":"Cancer Discov"},{"key":"BFnature18600_CR26","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","volume":"123","author":"E Traer","year":"2014","unstructured":"Traer, E. et al. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood 123, 1516\u20131524 (2014)","journal-title":"Blood"},{"key":"BFnature18600_CR27","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-05-2193","volume":"65","author":"EL Jackson","year":"2005","unstructured":"Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280\u201310288 (2005)","journal-title":"Cancer Res."},{"key":"BFnature18600_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","volume":"158","author":"DD Shao","year":"2014","unstructured":"Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171\u2013184 (2014)","journal-title":"Cell"},{"key":"BFnature18600_CR29","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","volume":"18","author":"T Shimizu","year":"2012","unstructured":"Shimizu, T. et al. The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316\u20132325 (2012)","journal-title":"Clin. Cancer Res."},{"key":"BFnature18600_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.molcel.2011.02.008","volume":"41","author":"C Fellmann","year":"2011","unstructured":"Fellmann, C. et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol. Cell 41, 733\u2013746 (2011)","journal-title":"Mol. Cell"},{"key":"BFnature18600_CR31","unstructured":"Taylor, J., Schenck, I., Blankenberg, D. & Nekrutenko, A. in Current Protocols in Bioinformatics (eds Baxevanis, A. D. et al. ) Ch. 10, Unit 10.5 (Wiley, 2007)"},{"key":"BFnature18600_CR32","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010)","journal-title":"Cancer Res."},{"key":"BFnature18600_CR33","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2015.38","volume":"34","author":"JT Poirier","year":"2015","unstructured":"Poirier, J. T. et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene 34, 5869\u20135878 (2015)","journal-title":"Oncogene"},{"key":"BFnature18600_CR34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","volume":"4","author":"M DuPage","year":"2009","unstructured":"DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols 4, 1064\u20131072 (2009)","journal-title":"Nature Protocols"},{"key":"BFnature18600_CR35","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/emboj.2013.204","volume":"32","author":"M Huch","year":"2013","unstructured":"Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5\/R-spondin axis. EMBO J. 32, 2708\u20132721 (2013)","journal-title":"EMBO J."},{"key":"BFnature18600_CR36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1101\/gad.232082.113","volume":"28","author":"M Saborowski","year":"2014","unstructured":"Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85\u201397 (2014)","journal-title":"Genes Dev."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature18600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature18600","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature18600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:53:14Z","timestamp":1684417994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature18600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":36,"journal-issue":{"issue":"7609","published-print":{"date-parts":[[2016,6,30]]}},"alternative-id":["BFnature18600"],"URL":"https:\/\/doi.org\/10.1038\/nature18600","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,22]]},"assertion":[{"value":"23 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.R. is a member of the scientific advisory board of Novartis, AstraZeneca, and Chugai Pharmaceutical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}